CCL2 [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
====== CCL2 ======


This gene is one of several [[cytokine]] [[gene]]s clustered on the q-arm of [[chromosome 17]]. 
----
This chemokine is a member of the CC subfamily which is characterized by two adjacent [[cysteine]] residues. This cytokine displays chemotactic activity for [[monocyte]]s and [[basophil]]s but not for [[neutrophil]]s or [[eosinophil]]s. It has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like [[psoriasis]], [[rheumatoid arthritis]] and [[atherosclerosis]]. It binds to [[chemokine receptor]]s [[CCR2]] and CCR4.
----
[[CCL2]] might be a key regulator in the above endogenous [[neuroblast]]s migration. Moreover, delayed CCL2 administration may provide a promising therapeutic strategy for late [[neurogenesis]] post-trauma
((Wu N, Sun X, Zhou C, Yan J, Cheng C. Neuroblasts migration under control of reactive astrocyte-derived BDNF: a promising therapy in late neurogenesis after traumatic brain injury. Stem Cell Res Ther. 2023 Jan 5;14(1):2. doi: 10.1186/s13287-022-03232-0. PMID: 36600294.)).
----
CCL2 ([[MCP-1]]) and CCL5 (RANTES) are pro-inflammatory [[chemokine]]s that mediate [[neuroimmune]] [[response]]s to acute [[insult]]s, and aspects of [[brain injury]] and [[neurodegenerative disease]]s; however, a blood-to-brain transport system has not been evaluated for either [[chemokine]] in vivo. Therefore, Quaranta et al. determined whether CCL2 and CCL5 in blood can cross the intact BBB and enter the brain. Using CD-1 mice, they found that 125I-labeled CCL2 and CCL5 crossed the BBB, and entered the brain parenchyma. They next aimed to identify the mechanisms of 125I-CCL2 and 125I-CCL5 transport in an in-situ brain perfusion model. They found that both heparin and [[eprodisate]] inhibited brain uptake of 125I-CCL2 and 125I-CCL5 in situ, whereas antagonists of their receptors, CCR2 or CCR5 respectively, did not, suggesting that heparan sulfates at the endothelial surface mediate BBB transport. Finally, they showed that CCL2 and CCL5 transport across the BBB increased following a single injection of 0.3mg/kg [[lipopolysaccharide]]. These data demonstrate that CCL2 and [[CCL5]] in the brain can derive, in part, from the circulation, especially during systemic [[inflammation]]. Further, binding to the BBB-associated heparan sulfate is a mechanism by which both chemokines can cross the intact BBB, highlighting a novel therapeutic target for treating [[neuroinflammation]].The work demonstrates that CCL2 and CCL5 can cross the intact BBB, and that transport is robustly increased during [[inflammation]]. These data suggest that circulating CCL2 and CCL5 can contribute to brain levels of each chemokine. They further showed that the transport of both chemokines is inhibited by [[heparin]] and [[eprodisate]], suggesting that CCL2/CCL5-heparan sulfate interactions could be therapeutically targeted to limit accumulation of these chemokines in the brain
((Quaranta DV, Weaver RR, Baumann KK, Fujimoto T, Williams LM, Kim HC, Logsdon AF, Omer M, Reed MJ, Banks WA, Erickson MA. [[Transport]] of the pro-inflammatory chemokines [[CCL2]] (MCP-1) and [[CCL5]] (RANTES) across the intact mouse [[blood-brain barrier]] is inhibited by [[heparin]] and [[eprodisate]] and increased with systemic inflammation. J Pharmacol Exp Ther. 2022 Oct 30:JPET-AR-2022-001380. doi: 10.1124/jpet.122.001380. Epub ahead of print. PMID: 36310035.)).